CRT-D Cost-Effectiveness Disputed; JACC Editorial Says More Studies Needed
This article was originally published in The Gray Sheet
Executive Summary
Additional head-to-head trials are necessary to assess whether the benefit of cardiac resynchronization therapy with defibrillation (CRT-D) justifies its high cost, according to Mark Hlatky, MD, Stanford University
You may also be interested in...
U.S. Should Create Cost-Effectiveness Group To Advise CMS – NEJM Editorial
The U.S. government should establish an institute similar to the UK's National Institute for Clinical Excellence to help CMS apply cost-effectiveness criteria to coverage and payment decisions, according to an editorial in the Oct. 6 New England Journal of Medicine
CRT-D May Reap Higher CE Ratio Than Defibrillation Alone – Annals Editorial
Implantable cardioverter defibrillators with resynchronization (CRT-D) are likely to prove more cost-effective than ICD therapy alone for patients with moderate-to-severe heart failure, according to Stephen Pauker, MD, et al., Tufts University
CRT-P Versus CRT-D: A Match-Up Likely Never To Be Seen – NEJM Editoral
Cardiac resynchronization with cardioverter defibrillation devices (CRT-D) will continue to be used more often than CRT-alone, even though the latter option may actually be better for some heart failure patients, according to John Jarcho, MD, Brigham & Women's Hospital, Boston